Financial Performance - Revenue for the third quarter was RMB 485,799,506.29, a decrease of 15.51% compared to the same period last year[4] - Net profit attributable to shareholders was RMB 99,435,565.54, down 58.04% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 84,926,745.33, a decline of 63.74% compared to the previous year[4] - The net cash flow from operating activities was RMB 192,325,709.34, a decrease of 57.11% year-on-year[4] - Basic earnings per share were RMB 0.13, down 59.38% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 121.46% year-to-date due to intensified competition, declining sales revenue, and a decrease in the fair value of biological assets[11] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 136.47% year-to-date, primarily due to similar factors as above[11] - Cash flow from operating activities decreased by 57.11% year-to-date, mainly due to reduced sales collections while employee compensation remained stable compared to the previous year[11] - Basic earnings per share decreased by 120.45% year-to-date, reflecting the impact of increased competition and declining sales revenue and gross margin[11] - Diluted earnings per share decreased by 120.45% year-to-date, consistent with the basic earnings per share decline[11] - Net profit attributable to shareholders for the current reporting period decreased by 58.04% due to intensified competition and declining sales revenue[11] - Net profit attributable to shareholders after deducting non-recurring gains and losses for the current reporting period decreased by 63.74%[11] - Basic earnings per share for the current reporting period decreased by 59.38% due to similar competitive pressures[11] - Diluted earnings per share for the current reporting period decreased by 59.38%, reflecting the same trends[11] Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,525,184,807.98, a decrease of 5.01% from the end of the previous year[4] - Equity attributable to shareholders was RMB 8,002,435,682.20, down 3.34% compared to the end of the previous year[4] - As of September 30, 2024, the company's total current assets amounted to RMB 5.33 billion, a decrease from RMB 7.12 billion on December 31, 2023[18] - The total non-current assets as of September 30, 2024, were CNY 4,191,072,779.02, significantly higher than CNY 2,905,192,290.36 as of December 31, 2023, marking an increase of about 44.2%[21] - Total liabilities as of September 30, 2024, were CNY 1,534,350,209.75, down from CNY 1,746,119,215.39 at the end of 2023, a decrease of approximately 12.1%[20] - The total assets as of September 30, 2024, were CNY 9,525,184,807.98, compared to CNY 10,027,159,630.47 at the end of 2023, indicating a decline of about 5.0%[21] - The total equity attributable to shareholders as of September 30, 2024, was CNY 8,002,435,682.20, down from CNY 8,279,315,724.35 at the end of 2023, a decrease of about 3.4%[21] Cash Flow and Investments - The company's cash and cash equivalents decreased from RMB 2.86 billion at the end of 2023 to RMB 1.84 billion as of September 30, 2024[18] - The company's trading financial assets increased significantly from RMB 373.35 million to RMB 1.38 billion during the same period[18] - The company reported a net interest income of CNY 82,526,990.66 for the first three quarters of 2024, compared to CNY 108,316,598.07 in the same period of 2023, reflecting a decrease of approximately 23.9%[22] - Cash inflow from operating activities for the first three quarters of 2024 is 1,367,691,390.73, down from 1,874,131,001.01 in 2023, showing a decrease in cash generation[27] - The cash inflow from investment activities totaled 2,508,098,115.21, significantly increasing from 528,639,464.14 in the first three quarters of 2023[28] - The net cash flow from investment activities was -950,050,766.71, worsening from -137,147,755.87 in the same period of 2023[28] - The cash outflow from financing activities was 248,828,091.97, down from 333,289,197.75 in the first three quarters of 2023[29] - The net increase in cash and cash equivalents was -1,013,522,516.10, compared to -8,194,783.60 in the same period of 2023[29] - The ending balance of cash and cash equivalents was 1,840,124,511.87, a decrease from 2,891,274,796.93 at the end of the same period in 2023[29] - The cash inflow from recovering investments was 2,307,885,508.22, a substantial increase from 501,496,756.80 in the first three quarters of 2023[28] - The cash outflow for purchasing fixed assets and intangible assets was 188,019,727.66, up from 149,651,195.84 in the same period of 2023[28] - The cash paid for long-term assets was 3,270,129,154.26, significantly higher than 426,076,500.00 in the first three quarters of 2023[28] Operational Performance - The company signed new contracts worth approximately RMB 1.4 billion in the first three quarters, with a total order backlog of about RMB 2.65 billion as of the end of the reporting period[16] - The company reported a foreign exchange loss of -190,401,449.68 in the first three quarters of 2024, compared to -108,513,934.09 in 2023, indicating increased volatility in currency exchange[23] - The company experienced a credit impairment loss of -11,477,062.92 in the first three quarters of 2024, compared to -3,187,147.18 in 2023, reflecting worsening credit conditions[23] - The operating profit for the first three quarters of 2024 is -69,661,013.72, down from 392,084,940.00 in 2023, indicating a substantial decrease in operational performance[23] - The total comprehensive income for the first three quarters of 2024 is -79,103,195.69, a stark contrast to 336,381,200.67 in the previous year[25] - Basic and diluted earnings per share for the first three quarters of 2024 are both reported at -0.09, compared to 0.44 in 2023, indicating a loss per share[25] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 72,246, with the top ten shareholders holding significant stakes[12] - There were no changes in the top 10 shareholders due to securities lending or borrowing activities[15] Strategic Outlook - The company has not disclosed any new product or technology developments in the recent reporting period[16] - The company has not indicated any market expansion or acquisition strategies in the latest report[16] - The company has advised investors to be cautious due to various factors affecting order execution[16]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，於 第 四 屆 董 事 會 第 十 次 會 議 中，董 事 會 決 議 及 批 准（其 中 包 括）：(i)建 議 變 更 本 公 司 註 冊 股 本；及(ii)建議修訂本公司組織章程細則（「組織章程細則」）。 建議變更本公司註冊股本 由於包括(i)儲 備 資 本 化；(ii)根 據2019年A股限制性股票激勵計劃及2021年A股 限 制性股票激勵計劃購回及註銷A股 限 制 性 股 票；及(iii)終 止2021年A股限制性股 票 激 勵 計 劃，並 購 回 及 註 銷 其 項 下 已 授 出 但 尚 未 解 除 限 售 的A股限制性股票等 因 素，本 公 司 的 註 冊 股 本 ...

北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） JOINN LABORATORIES (CHINA) CO., LTD. | | 董事委員會 | | 薪酬與考核 | | | | --- | --- | --- | --- | --- | --- | | 董事 | | 戰略委員會 | 委員會 | 審計委員會 | 提名委員會 | | 執行董事 | | | | | | | 馮宇霞女士 | （主 席） | C | | | M | | 左從林先生 | | M | M | | | | 高大鵬先生 | | | | | | | 孫雲霞女士 | | M | | | | | 獨立非執行董事 | | | | | | | 孫明成先生 | | | M | C | | | 翟永功博士 | | | | M | C | | 歐小傑先生 | | M | C | | M | | 張帆先生 | | | | M | | 附 註： C 相關董事委員會的主席 M 相關董事委員會的成員 中 國，北 京，2024年10月30日 （股 份 代 號：6127） 董事名單以及其角色及職能 北京昭衍 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） (1)執行董事辭任 及 (2)建議委任執行董事 執行董事辭任 北京昭衍新藥研究中心股份有限公司（「本公司」）董 事（「董 事」，各 自 為 一 名「董 事」）會（「董事會」）於近日收到姚大林博士（「姚博士」）的 辭 職 函。據 此，姚 博 士 因 工 作 安 排 辭 去 本 公 司 執 行 董 事 及 本 公 司 副 總 經 理 職 務。姚 博 士 已 確 認，彼 與 董 事 會 並 無 意 見 分 歧，亦 無 其 他 因 辭 任 而 需 知 會 股 東 的 事 宜。姚 博 士 辭 去 上 述 職 務 後，將 繼 續 在 公 司 其 ...

Financial Performance - Revenue for Q3 2024 was RMB 485,799,506.29, a decrease of 15.51% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was RMB 99,435,565.54, down 58.04% year-on-year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was RMB 84,926,745.33, a decline of 63.74% compared to the previous year[2] - Year-to-date net profit attributable to shareholders was RMB -70,307,075.11, a decrease of 121.46% compared to the same period last year[2] - Year-to-date revenue was RMB 1,335,156,050.40, down 15.87% year-on-year[2] - Basic earnings per share for Q3 2024 was RMB 0.13, a decrease of 59.38% compared to the same period last year[3] - The net profit for Q3 2024 was -74,244,009.94 RMB, a significant decrease compared to the net profit of 326,197,002.65 RMB in Q3 2023, representing a decline of approximately 122.7%[22] - Operating profit for Q3 2024 was -69,661,013.72 RMB, compared to an operating profit of 392,084,940.00 RMB in the same period last year, indicating a substantial drop[22] - Total operating revenue for the first three quarters of 2024 was CNY 1,335,156,050.40, a decrease of 15.8% compared to CNY 1,587,079,779.38 in the same period of 2023[20] - The total comprehensive income for Q3 2024 was -79,103,195.69 RMB, compared to 336,381,200.67 RMB in Q3 2023, indicating a decline of approximately 123.5%[23] Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,525,184,807.98, a decrease of 5.01% from the end of the previous year[3] - Total assets amounted to CNY 9,525,184,807.98, down from CNY 10,027,159,630.47, a decrease of 5.0%[19] - Total liabilities decreased to CNY 1,534,350,209.75 from CNY 1,746,119,215.39, a reduction of 12.1%[19] - The company's total equity decreased to CNY 7,990,834,598.23 from CNY 8,281,040,415.08, a decline of 3.5%[19] - Inventory decreased to CNY 1,631,793,427.45 from CNY 1,863,081,944.56, a decrease of 12.4%[18] Cash Flow - The net cash flow from operating activities year-to-date was RMB 192,325,709.34, down 57.11% year-on-year[2] - The cash flow from operating activities for the first three quarters of 2024 was 192,325,709.34 RMB, a decrease from 448,440,218.42 RMB in the same period of 2023, showing a decline of approximately 57.1%[24] - The total cash inflow from investment activities for the first three quarters of 2024 was 2,508,098,115.21 RMB, a significant increase from 528,639,464.14 RMB in the same period of 2023[24] - The net cash flow from investing activities was -950,050,766.71, compared to -137,147,755.87 in the previous period, indicating a significant increase in cash outflow for investments[25] - The total cash outflow from financing activities was 248,828,091.97, down from 333,289,197.75 in the previous period, reflecting a reduction in financing costs[25] - The net increase in cash and cash equivalents was -1,013,522,516.10, compared to -8,194,783.60 in the previous period, showing a substantial decline in liquidity[25] - The ending balance of cash and cash equivalents was 1,840,124,511.87, down from 2,891,274,796.93 in the previous period, indicating a decrease in available cash[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 72,246, with no preferred shareholders having voting rights[9] - The largest shareholder, Feng Yuxia, holds 167,160,633 shares, representing 22.30% of the total shares[10] - The second largest shareholder, HKSCC Nominees Limited, holds 118,974,786 shares, accounting for 15.87%[10] - The company has not reported any changes in the top 10 shareholders due to margin trading or stock lending activities during the reporting period[14] - The top 10 shareholders include several institutional investors, with the largest being a medical index fund[12] Business Operations - The contribution of laboratory service business to net profit year-to-date was RMB -1,705,100, a decline of 100.55% compared to the previous year[4] - The fair value change of biological assets resulted in a net loss of RMB 17,698,420.00 year-to-date[4] - The total new signed orders for the first three quarters amounted to approximately RMB 1.4 billion, with the total outstanding orders at approximately RMB 2.65 billion as of the report date[15] - The outstanding orders execution is influenced by various factors, and investors are advised to pay attention to investment risks[15] - The company has not disclosed any new product developments or market expansion strategies in the current report[11] - The company is focusing on expanding its market presence and enhancing its product development capabilities, although specific new products or technologies were not detailed in the report[20] Research and Development - Research and development expenses for Q3 2024 were 71,085,657.06 RMB, down from 77,639,680.27 RMB in Q3 2023, reflecting a decrease of about 8.1%[22] Accounting and Standards - The company’s financial statements are unaudited as of September 30, 2024[16] - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[26]

Financial Performance - JOINN Laboratories reported a revenue of RMB 1.2 billion for the first half of 2024, representing a year-on-year increase of 25%[6]. - The company achieved a net profit of RMB 300 million, up 30% compared to the same period last year[6]. - Revenue for the first half of 2024 was RMB 849,357,000, a decrease of 16.1% compared to RMB 1,012,077,000 in the same period of 2023[12]. - Gross profit for the first half of 2024 was RMB 211,301,000, down 52.8% from RMB 447,799,000 in the first half of 2023[12]. - The company reported a net loss attributable to equity shareholders of RMB 169,742,000 for the first half of 2024, a decline of 287.3% compared to a profit of RMB 90,627,000 in the same period of 2023[12]. - The gross margin decreased to 24.9% in the first half of 2024 from 44.2% in the same period of 2023, a reduction of 19.3 percentage points[12]. - The company reported a net loss of RMB 172.2 million for the six months ended June 30, 2024, compared to a profit of RMB 89.5 million for the same period in 2023, resulting in a net profit margin of -20.3%[30]. - The company reported a total comprehensive loss for the six months ended June 30, 2024, was RMB 169,213 thousand, compared to a total comprehensive income of RMB 102,760 thousand in 2023[91]. Market Expansion and Strategy - JOINN Laboratories plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2025[6]. - The company is exploring potential acquisitions to enhance its capabilities in biopharmaceuticals, with a budget of RMB 500 million allocated for this purpose[6]. - The company aims to enhance its market share and international influence in the non-clinical pharmacology and toxicology evaluation business, focusing on expanding upstream and downstream capabilities[36]. - The company plans to improve service quality by establishing new technologies and methods, optimizing internal management systems, and expanding production capacity to maintain its market share in non-clinical research services[37]. Research and Development - The company is investing RMB 200 million in R&D for new drug development, focusing on oncology and rare diseases[6]. - The company is focusing on enhancing its R&D service capabilities and quality, leveraging AI and information technology to improve operational efficiency[13]. - The company aims to expand its upstream and downstream business capabilities and build a new drug discovery platform to enhance one-stop service levels[13]. - The company is continuously updating and improving its non-clinical safety evaluation system for innovative drugs, including new types of ADC and PROTAC drugs[19]. - The company has established a high-level technical team of over 40 people and set up laboratories in Suzhou and Beijing for drug quality research and testing[23]. Operational Efficiency - JOINN Laboratories aims to enhance operational efficiency, targeting a reduction in operational costs by 10% by the end of 2024[6]. - The company plans to enhance its project management capabilities and operational efficiency to ensure the smooth launch of new experimental facilities[37]. - The company will continue to improve its performance evaluation, training, and compensation systems to boost employee productivity and support overall strategic goals[38]. Facilities and Compliance - The construction of the Suzhou Zhaoyan Phase II facility, covering 20,000 square meters, has been completed in 2023 and is expected to be operational by early 2025, enhancing business throughput and performance growth[15]. - The company has successfully passed the FDA GLP inspection for its Beijing facility for the third time, demonstrating its compliance with international GLP operational management standards[17]. - The company is actively advancing the construction of the Guangzhou Zhaoyan Anping base to support strategic planning and business needs[15]. Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ending June 30, 2024[42]. - As of June 30, 2024, the company has a total of 749,888,699 issued shares, including 630,893,493 A shares and 118,995,206 H shares[44]. - Major shareholder Mr. Zhou holds 74,725,981 A shares, representing approximately 11.84% of the A shares and 9.96% of the total shares[46]. Financial Position and Assets - Total assets as of June 30, 2024, were RMB 9,661,274,000, a decrease of 3.6% from RMB 10,027,159,000 at the end of 2023[12]. - Cash and cash equivalents as of June 30, 2024, were RMB 2,158.2 million, a decrease of 24.6% from RMB 2,862.9 million as of December 31, 2023[32]. - The company reported a total of RMB 1,843,164,000 in financial assets at fair value through profit or loss as of June 30, 2024, an increase of 92.5% from RMB 961,138,000 as of December 31, 2023[132]. Employee and Talent Management - The company has a professional service team of 2,585 members as of June 30, 2024, reflecting ongoing talent development initiatives[14]. - The company is actively applying for national and regional talent policies to ensure long-term stability of its talent pool[14]. - The company will actively recruit industry experts with overseas experience to strengthen its domestic team's international business capabilities[37]. Related Party Transactions - The company has significant related party transactions with entities controlled by major shareholders, including Shutaishen (Beijing) Biopharmaceutical Co., Ltd.[163]. - Revenue from services provided to Shuyishen Group decreased to RMB 10,385,000 for the six months ended June 30, 2024, down from RMB 31,542,000 for the same period in 2023, representing a decline of approximately 67.0%[166].

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 849,357 thousand, a decrease of 16.1% compared to RMB 1,012,077 thousand for the same period in 2023[2] - Gross profit for the same period was RMB 211,301 thousand, down 52.8% from RMB 447,799 thousand in 2023[2] - The net loss attributable to equity shareholders for the six months ended June 30, 2024, was RMB (169,742) thousand, compared to a profit of RMB 90,627 thousand in 2023, representing a decline of 287.3%[2] - Total comprehensive loss for the period was RMB (169,213) thousand, compared to a comprehensive income of RMB 102,760 thousand in the previous year[4] - Basic and diluted loss per share for the period was RMB (0.23), compared to earnings per share of RMB 0.12 in the same period last year[4] - The company reported a significant increase in research and development expenses, totaling RMB 47,840 thousand for the period, compared to RMB 56,933 thousand in 2023[3] - Total revenue from external customers for the six months ended June 30, 2024, was RMB 849,357,000, a decrease from RMB 1,012,077,000 for the same period in 2023, representing a decline of approximately 16.1%[20] - Reported segment gross profit for the six months ended June 30, 2024, was RMB 211,301,000, down from RMB 447,799,000 in the same period of 2023, indicating a decrease of about 52.8%[18] - The gross profit margin for the six months ended June 30, 2024, was approximately 24.8%, down from 44.3% in the same period of 2023[18] - The company reported a decrease in government grants received, totaling RMB 9,571,000 for the six months ended June 30, 2024, compared to RMB 15,108,000 in 2023, a decline of about 36.5%[24] - The company's profit decreased from RMB 89.5 million for the six months ended June 30, 2023, to a loss of RMB 172.2 million for the six months ended June 30, 2024, resulting in a net profit margin drop from 8.8% to -20.3%[66] Assets and Liabilities - The company's total assets as of June 30, 2024, were RMB 8,559,794 thousand, compared to RMB 8,281,041 thousand as of December 31, 2023[6] - Non-current assets increased to RMB 4,168,390 thousand as of June 30, 2024, from RMB 2,905,192 thousand at the end of 2023[5] - Current liabilities decreased to RMB 5,492,884 thousand as of June 30, 2024, from RMB 7,121,967 thousand at the end of 2023[5] - The company's total liabilities as of June 30, 2024, were RMB 1,938,946,000, down from RMB 2,065,701,000 as of December 31, 2023, reflecting a decrease of approximately 6.1%[21] - Trade receivables, net of loss provisions, amounted to RMB 202,397,000 as of June 30, 2024, slightly down from RMB 206,014,000 as of December 31, 2023[35] - Trade payables increased to RMB 64,587,000 as of June 30, 2024, compared to RMB 43,323,000 as of December 31, 2023[37] - As of June 30, 2024, cash and cash equivalents were RMB 2,158.2 million, a decrease of 24.6% from RMB 2,862.9 million as of December 31, 2023[68] - The capital debt ratio remained relatively stable at 18.1% as of June 30, 2024, compared to 17.4% as of December 31, 2023[69] Operational Developments - The company has a professional service team of 2,585 employees as of June 30, 2024, reflecting ongoing investment in talent development[40] - The construction of the Suzhou Zhaoyan Phase II facility, covering 20,000 square meters, has been topped out in 2023 and is expected to be operational by early 2025, enhancing business throughput and performance growth[41] - A new 22,000 square meter supporting facility in Suzhou is under renovation and is projected to be completed and operational by the end of 2024, aimed at providing a better working environment for employees[41] - The wholly-owned subsidiary Guangxi Weimei Biotechnology Co., Ltd. plans to initiate the construction of a non-human primate model animal testing facility in the second half of 2024, focusing on enhancing animal welfare[42] - The company successfully passed the FDA GLP inspection for its Beijing facility in the first half of 2024, marking the fifth successful inspection for both the Beijing and Suzhou facilities, ensuring compliance with international GLP standards[43] - The company has developed and optimized various ophthalmic disease models, including laser-induced mouse models and rabbit autoimmune uveitis models, to meet diverse market research needs[43] - The company has improved various drug administration methods for central nervous system drugs, establishing long-term catheter methods and verifying their effectiveness[45] - The company has established a high-level technical team of over 40 people for quality research and testing of innovative drugs, including protein drugs and gene therapy products[51] - The company has maintained a stable growth trend in the number of ongoing projects, with a total order amount of approximately RMB 2.9 billion, providing a guarantee for future performance[52] Strategic Initiatives - The company aims to enhance its non-clinical CRO business and expand upstream and downstream capabilities, including early drug discovery and clinical CRO services[71] - Plans to expand capacity include the completion of a 20,000 square meter facility in Suzhou, expected to be operational by early 2025[74] - The company intends to recruit more industry experts with overseas experience to strengthen its international business capabilities[73] - The company aims to expand its registration team to enhance international registration capabilities, addressing the growing demand for registrations[75] - The company plans to enhance its laboratory scale and team size for clinical testing, particularly in the U.S., to better support clinical trial needs[75] - The internationalization strategy includes supporting BIOMERE to expand its laboratory facilities in North America to increase service throughput[77] - The company will strengthen its business development team in the U.S. to enhance market promotion and leverage BIOMERE's brand reputation[77] Shareholder Information - The company did not recommend any interim dividend for the six months ended June 30, 2024, consistent with the previous year[33] - The company approved a dividend of RMB 0.16 per ordinary share for the 2023 profit distribution plan, to be paid in July 2024[33] - No interim dividend will be paid to shareholders for the six months ending June 30, 2024[80] Compliance and Governance - The company has adopted corporate governance codes in compliance with the Hong Kong Stock Exchange regulations[78] - The audit committee reviewed the interim financial results for the six months ended June 30, 2024, and confirmed compliance with relevant accounting standards[92]

Financial Performance - The company reported a revenue of 500 million yuan for the first half of 2024, representing a 20% increase compared to the same period last year[6]. - The company's operating revenue for the first half of 2024 was RMB 849,356,544.11, a decrease of 16.08% compared to RMB 1,012,077,288.18 in the same period last year[15]. - The net profit attributable to shareholders of the listed company was a loss of RMB 169,742,640.65, representing a decline of 287.30% from a profit of RMB 90,627,154.09 in the previous year[15]. - The net cash flow from operating activities was RMB 157,716,643.31, down 35.94% from RMB 246,209,748.37 in the same period last year[15]. - The total assets decreased by 3.65% to RMB 9,661,273,688.68 from RMB 10,027,159,630.47 at the end of the previous year[15]. - Basic earnings per share for the first half of 2024 were -0.23 yuan, a decrease of 291.67% compared to 0.12 yuan in the same period last year[16]. - The weighted average return on net assets was -2.08%, a decrease of 3.18 percentage points from 1.10% in the previous year[16]. - The company reported a net loss of RMB 23,535,770 from changes in the fair value of biological assets during the reporting period[16]. - The company reported a total non-recurring profit and loss of 28,652,307.04 RMB for the period, with significant contributions from government subsidies (8,901,549.99 RMB) and fair value changes of financial assets (9,798,498.01 RMB)[18]. Research and Development - Investment in R&D increased by 30% year-on-year, totaling 150 million yuan, focusing on innovative drug development and technology enhancements[6]. - The company has applied for 12 patents in drug quality research, with one granted and five published, enhancing its research capabilities[50]. - The company is expanding into human-derived multifunctional stem cell production and liver organoid platforms, aiming to provide iPSC reprogramming and organoid induction services[49]. - The company has developed a comprehensive drug screening platform that evaluates candidate molecules for efficacy, metabolism, and safety, enhancing development value[29]. - The company has established high-quality non-human primate experimental models, ensuring reliable data for drug safety evaluations[35]. Market Expansion and Strategy - The company expects a revenue growth forecast of 25% for the second half of 2024, driven by new product launches and market expansion strategies[6]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[6]. - A strategic acquisition of a biotech firm is in progress, expected to enhance the company's capabilities in drug development and testing services[6]. - The company has launched two new products in Q2 2024, contributing to a 5% increase in overall sales volume[6]. Operational Efficiency - The gross profit margin improved to 45%, up from 40% in the previous year, reflecting better cost management and pricing strategies[6]. - The company has maintained a strong cash position with 300 million yuan in cash reserves, ensuring liquidity for future investments[6]. - The company emphasizes the importance of quality management and regulatory compliance in its service delivery to enhance operational efficiency[20]. - The company has established a systematic procurement management SOP to ensure compliance with GLP standards for the procurement of experimental models and related supplies[21]. Environmental Responsibility - The company emphasizes the importance of environmental protection, with water resource usage reported at 13,592 cubic meters for the company and 87,118 cubic meters for its subsidiary in the first half of the year[74]. - The company has implemented a comprehensive environmental management system, conducting regular inspections and third-party assessments of wastewater, noise, and air emissions[73]. - The company has committed to reducing carbon emissions through various measures, including the use of energy-efficient LED lighting and electric vehicles[80]. - The company has established a waste recycling agreement with third-party service providers to ensure proper waste management and disposal[77]. Talent and Human Resources - The company is experiencing a talent risk due to the long training cycle for industry professionals and the increasing difficulty in attracting and retaining talent[63]. - The company is implementing a talent development program to identify high-potential employees and enhance management capabilities[39]. - The company has a professional service team of 2,585 members as of June 30, 2024[40]. Compliance and Governance - The company received a warning letter from the China Securities Regulatory Commission regarding a 8.16% reduction in shareholding without timely disclosure[83]. - The company has strengthened its compliance with legal regulations following the warning letter received[83]. - There were no significant lawsuits or arbitration matters during the reporting period[83]. Financial Position - The total liabilities stood at CNY 1,746,032,260.24, slightly down from CNY 1,746,119,215.39, indicating a marginal decrease of 0.005%[98]. - The equity attributable to shareholders decreased to CNY 7,916,012,413.20 from CNY 8,279,315,724.35, a decline of approximately 4.39%[98]. - The company's current assets totaled CNY 5,492,884,034.54, down from CNY 7,121,967,340.11, indicating a decrease of about 22.87%[96]. - The company's inventory as of June 30, 2024, was CNY 1,632,144,111.85, down from CNY 1,863,081,944.56, a decrease of about 12.35%[96]. Shareholder Information - The total number of shares decreased from 749,888,699 to 749,477,334 after the repurchase and cancellation of 411,365 restricted shares[88]. - The top shareholder, Feng Yuxia, holds 167,160,633 shares, representing 22.29% of the total shares[89]. - HKSCC NOMINEES LIMITED is the second-largest shareholder with 118,975,060 shares, accounting for 15.87%[89]. - The company has repurchased 1,735,600 A shares, accounting for 0.2314% of total shares, with a total expenditure of approximately RMB 28.28 million[72].

重要内容提示： 每股分配比例 证券代码：603127 证券简称：昭衍新药 公告编号：2024-035 北京昭衍新药研究中心股份有限公司 2023 年年度 A 股 权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 A 股每股现金红利 0.16 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除息日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/7/30 | － | 2024/7/31 | 2024/7/31 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 6 月 20 日的 2023 年年度股东大会、2024 年第二次 A 股 类别股东会议及 2024 年第二次 H 股类别股东会议审议通过。 二、 分配方案 1. 发放年度：2023 年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记 ...

发言人 39:38 明白，然后刚才也提到有几个建设的投入，就不知道 pad pack 这块，咱们今年大概是就从数字化一点的， 大概是多少？应该就是 11 亿左右的规模，你做一个规就是全部加总在一起。对对对，就各个过去的措施， 未来就比如说明年或者再往后一点的时间，每年还是这个规划。我刚才也介绍了，就是新增的产能还是要 看需求，有需求我们才会释放，没有需求就是这些。 发言人 40:31 好的，我看现在线上也没有举手的投资者了。那咱们今天线上交流的这个成果也非常的充分。那就非常感 谢罗总的时间和各位投资者的参与。以后大家如果对公司有进一步的问题，也欢迎随时和朝阳的 IR 团队或 者和国生医药团队做进一步的交流。那么就谢谢罗总，谢谢各位投资者的参与，感谢大家，再见。好，谢 谢罗总，再见。 发言人 00:32 发言人 03:12 明白，然后刚才您也提到了价格这块的情况。现在看的话，这个价格战的大概是到了一个什么样的阶段？ 然后后续咱们觉得这个行业里面价格还有下降的可能性吗？从目前我们的价格在一季度到现在，一直到现 在，都是基本上是保持稳定的。其实应该说从去年年底到一季度到现在，基本上都是维持现在这样的一个 价格。我们 ...